Dihydroergotamine Mesylate Nasal Spray, Metered
Product Images NDC 69097-503

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate Nasal (NDC 69097-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 01

Chemical structure of dihydroergotamine mesylate showing its molecular formula C33H37N5O5•CH4O3S and molecular weight 679.78.*

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 02

A graph showing the estimated probability of patient response within four hours after a single 2 mg dose of dihydroergotamine mesylate nasal spray compared to placebo. The x-axis represents time from first dose in hours, and the y-axis shows the estimated probability of response to study medication as a percentage. The dihydroergotamine mesylate nasal spray curve demonstrates higher response rates over time versus placebo.*

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 03

A line chart illustrating the estimated probability of patients responding to Dihydroergotamine mesylate nasal spray compared to placebo over four hours following dosing. The x-axis represents time from first dose in hours, and the y-axis shows estimated probability of response in percentage.*

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 04

A line chart showing the estimated probability of patients using additional treatments for migraine over 24 hours after using either Dihydroergotamine mesylate nasal spray 2 mg or placebo. The x-axis represents hours after the first spray, and the y-axis represents the estimated probability of additional treatment use. The chart compares curves for the nasal spray and placebo groups.*

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 05

Label for Dihydroergotamine Mesylate Nasal Spray 4 mg/mL (1 mL per vial) by Cipla USA Inc. The label notes it is for nasal use only and not for injection. It includes dosage strength, manufacturer information, a barcode, and a QR code. The label is primarily white with blue and black text.*

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 06

Packaging label for Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL strength, a metered nasal spray by Cipla USA Inc. The label indicates the package contains 1 vial and 1 sprayer, states it is not for individual sale, and specifies use for nasal administration only, not for injection. The label includes storage instructions and manufacturer information.*

FDA Label Image

Eb13b2de 29b4 450d Bafc 396ac7d771b9 07

Label for Dihydroergotamine Mesylate Nasal Spray 4 mg/mL (1 mL/vial) by Cipla USA Inc. The label includes dosage strength and form, NDC 69097-503-27, usage instructions indicating nasal use only and not for injection, a list of inactive ingredients, and storage instructions. The packaging is designed for a metered nasal spray with clear regulatory and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.